| P50 | author | Petr I. Nikitin | Q45396791 |
| | Maria Sidorova | Q57090595 |
| | Tatiana Arefieva | Q74266785 |
| | Tatiana Ksenevich | Q84535193 |
| P2093 | author name string | T L Krasnikova | |
| | E I Chazov | |
| | Zh D Bespalova | |
| | S I Provatorov | |
| | E A Noeva | |
| | A V Potekhina | |
| | B G Gorshkov | |
| | N B Kukhtina | |
| | N U Ruleva | |
| P2860 | cites work | The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-alpha accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo | Q24682472 |
| | Chemokines--chemotactic cytokines that mediate inflammation | Q29616433 |
| | Chemokines | Q29616435 |
| | Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. | Q31169263 |
| | Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty | Q32085300 |
| | Changing concepts of atherogenesis | Q33890391 |
| | Differential binding of chemokines to glycosaminoglycan subpopulations | Q34323127 |
| | Pathophysiology of coronary artery disease | Q34429470 |
| | Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines | Q34762409 |
| | Increased concentrations of inflammatory mediators in unstable angina: correlation with serum troponin T | Q35379064 |
| | Inflammation and restenosis after percutaneous coronary interventions | Q35903106 |
| | Chemokines in the pathogenesis of vascular disease | Q35932790 |
| | Regulation of protein function by glycosaminoglycans--as exemplified by chemokines | Q36161167 |
| | Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. | Q36453167 |
| | Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. | Q36511835 |
| | A Dominant Negative Inhibitor Indicates that Monocyte Chemoattractant Protein 1 Functions as a Dimer | Q36554378 |
| | Migration and function of Th17 cells | Q37550979 |
| | Identification of a glycosaminoglycan binding surface on human interleukin-8. | Q38334550 |
| | Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. | Q38343397 |
| | The peptide analogue of MCP-1 65-76 sequence is an inhibitor of inflammation | Q40111002 |
| | Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses | Q40925991 |
| | Lysine 58 and histidine 66 at the C-terminal alpha-helix of monocyte chemoattractant protein-1 are essential for glycosaminoglycan binding | Q40999171 |
| | Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function | Q41669976 |
| | Regulation of monocyte integrin expression by beta-family chemokines. | Q42476643 |
| | Efficacy and safety of rapamycin as compared to paclitaxel-eluting stents: a meta-analysis. | Q42984352 |
| | Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation | Q43800221 |
| | Response of serum C-reactive protein to percutaneous coronary intervention has prognostic value | Q44401488 |
| | Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice | Q45856496 |
| | Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B. | Q45999198 |
| | Comparison of the systemic levels of inflammatory markers after percutaneous coronary intervention with bare metal versus sirolimus-eluting stents. | Q46107936 |
| | Changes in CCR2 chemokine receptor expression and plasma MCP-1 concentration after the implantation of bare metal stents versus sirolimus-eluting stents in patients with stable angina | Q46822541 |
| | C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. | Q51219596 |
| | C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. | Q53492059 |
| | MCP-1: Structure/Activity Analysis | Q71544659 |
| | Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries | Q74452823 |
| | Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice | Q77231603 |
| | Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice | Q77340592 |
| | Increased levels of monocyte-related cytokines in patients with unstable angina | Q77753001 |
| | Inhibition of migration of monocytes and granulocytes in vivo by the peptide corresponding to sequence 65-76 of monocyte chemotactic protein-1 (MCP-1) | Q80067132 |
| | The peptide of sequence 66-77 of monocytic chemotactic protein (MCP-1) inhibits inflammation in experimental animals | Q82230494 |
| | Effects of synthetic monocyte chemotactic protein-1 fragment 65-76 on neointima formation after carotid artery balloon injury in rats | Q83179376 |
| | [Peptide fragment 66-77 of monocyte chemoattractant protein 1 and its retro-enantio analogue inhibits the migration of cells in vitro and in vivo] | Q83199518 |
| | Effect of the C-terminal domain peptide fragment (65-76) of monocytic chemotactic protein-1 (MCP-1) on the interaction between MCP-1 and heparin | Q84743284 |
| P433 | issue | 10 | |
| P921 | main subject | chemotaxis | Q658145 |
| | stable angina | Q3617336 |
| P304 | page(s) | 955-964 | |
| P577 | publication date | 2011-07-10 | |
| P1433 | published in | Inflammation Research | Q1819367 |
| P1476 | title | Synthetic peptide fragment (65-76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting | |
| P478 | volume | 60 | |